09:15 AM EDT, 06/04/2025 (MT Newswires) -- Cuprina Holdings Cayman ( CUPR ) said Wednesday that Cuprina MENA has completed a laboratory in Saudi Arabia to manufacture the company's Medifly maggot debridement therapy for chronic wound treatment and supply it across the Middle East and North Africa region.

The company said Cuprina MENA, its indirect 49%-owned associate, is working to obtain regulatory approvals to sell the therapy in the region.

In another development, the company said that Cuprina MENA has received exclusive rights from Biopharm UK to sell medicinal leeches across the Gulf Cooperation Council countries.